• Circio webcast presentation highlighted circVec data showing up to 60x higher AAV expression in vivo across heart, eye, CNS.
• Next-generation circVec 5.0 positioned to deliver 200x or more improvement versus mVec, based on early design work.
• In vivo cell-therapy work showed circVec expression lasting three months in spleen using a T-cell-tropic LNP at reduced dose.
• R&D collaboration footprint expanded to 12 gene-therapy projects, including top-5 pharma access to novel AAV capsids.
• Capital update cited NOK ~620 million raised across three rounds, with cash runway secured to 2030.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Circio Holding ASA published the original content used to generate this news brief on September 01, 2026, and is solely responsible for the information contained therein.